Immunosuppressants Market Size, Share, Growth, Trends, and Global Industry Analysis: By Drug Class (Corticosteroids, Monoclonal Antibodies (mAbs), Calcineurin Inhibitors, mTOR Inhibitors, Anti-Proliferative Agents, Others), By Indication (Organ Transplantation, Autoimmune Disorders, Non-Autoimmune Inflammatory Diseases), By Route of Administration (Oral, Parenteral), By Distribution Channel (Hospital pharmacies, Retail pharmacies, Online pharmacies) and Region Forecast 2020-2031

Immunosuppressants Market size was valued at US$ 40.2 billion in 2024 and is expected to reach US$ 99.3 billion by 2031, growing at a significant CAGR of 13.8% from 2025-2031. Immunosuppressants or anti-rejections are the medicinal substances, which prevent or inhibit the immune system activity. Immunosuppressants are most commonly used in organ transplantation, and autoimmune disorders such as Crohn’s disease, multiple sclerosis, rheumatoid arthritis, and among others.  Moreover, immunosuppressants are also used in some non-autoimmune inflammatory diseases such as ankylosing spondylitis.

Immunodeficiency is the major adverse effect associated with immunosuppressants as these drugs act non-selectively and increase the susceptibility to infections. In addition, dyslipidemia, peptic ulcers, hypertension, kidney injury, hyperglycemia, and hepatic injuries are other adverse effects of immunosuppressants. The market is growing at a significant CAGR owing to an increase in the prevalence of autoimmune disorders and the incidence of organ transplantation.

For instance, According to the World Health Organization, in 2014, approximately 119,873 organ transplantation cases were observed, which was an increase of about 1.8% from 2013. Furthermore, various pipeline products in the market are also expected to bolster the market over the forecast period. Acquisitions & mergers, collaborations, and product launches are the strategies followed by the companies to increase their revenue in the market.

Key Developments

• In September 2017, Zydus Cadila received FDA final approval for Mycophenolate Mofetil Immunosuppressant injection
• In April 2017, Sanofi received FDA approval for a Thymoglobulin immunosuppressant drug used for the prevention of acute kidney transplant rejection.